# EDGAR Filing Document

**Accession Number:** 0001014763
**File Stem:** 0001493152-26-004492
**Filing Date:** 2026-1
**Character Count:** 8400
**Document Hash:** c84a08ceb9bf228416abefa648d01155
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-004492.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001493152-26-004492

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260130

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ainos, Inc.
- **CENTRAL INDEX KEY:** 0001014763
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 751974352
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-46755
- **FILM NUMBER:** 26583474

**BUSINESS ADDRESS:**
- **STREET 1:** 3050 POST OAK BLVD,
- **STREET 2:** SUITE 510-T80
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056
- **BUSINESS PHONE:** (281) 898-6586

**MAIL ADDRESS:**
- **STREET 1:** 3050 POST OAK BLVD,
- **STREET 2:** SUITE 510-T80
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARILLO BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 19960516
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Taiwan Carbon Nano Technology Corp
- **CENTRAL INDEX KEY:** 0002034617

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** F5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 10F-2, NO. 66, SHENGYI 5TH RD.,
- **STREET 2:** HSINCHU COUNTY
- **CITY:** ZHUBEI
- **STATE:** F5
- **ZIP:** 302
- **BUSINESS PHONE:** 886 (037) 581999

**MAIL ADDRESS:**
- **STREET 1:** 10F-2, NO. 66, SHENGYI 5TH RD.,
- **STREET 2:** HSINCHU COUNTY
- **CITY:** ZHUBEI
- **STATE:** F5
- **ZIP:** 302

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Ainos, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**00902F402**

*(CUSIP Number)*

**Chun-Hsien Tsai**<br>14F.,No. 61, Sec. 4, New Taipei Bouleva,<br>Xinzhuang District<br>New Taipei City 242 F5 F5<br>886-37-581999

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/28/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00902F402** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Taiwan Carbon Nano Technology Corporation** | Name of reporting person<br>**Taiwan Carbon Nano Technology Corporation** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**F5** | Citizenship or place of organization<br>**F5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**989925.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**989925.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**989925.00** | Aggregate amount beneficially owned by each reporting person<br>**989925.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**13.62%** | Percent of class represented by amount in Row (11)<br>**13.62%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** The number of securities in Row 7 includes 989,925 shares of common stock, $0.01 par value, of Ainos, Inc., a Texas corporation (the "Issuer"), owned directly by Taiwan Carbon Nano Technology Corporation ("TCNT"), which are subject to a voting agreement between TCNT and Ainos Inc., a Cayman Islands corporation ("Ainos KY"). The percentage in Row 13 is based the sum of, (i) 4,812,634 shares of Common Stock outstanding as of November 13, 2025 as set forth in the Quarterly Report on Form 10-Q of the Issuer filed with the SEC on November 13, 2025, (ii) 950,000 shares of Common Stock granted and vested on November 25, 2025 as special stock awards, which were approved by the shareholders of Ainos, Inc. on November 7, 2025, (iii) 19,531 shares issued for service fee; (iv) 323,846 shares issued from December 5, 2025 to January 28, 2026 in the Issuer's at-the-market offering, and (v) 1,160,000 shares of Common Stock issued to ScentAI Inc. on December 30, 2025.

Except as set forth below, there are no changes to the information set forth in the Statement.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
Ainos, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3050 Post Oak Blvd, Suite 510-T80,, Houston,, TX, 77056

This Amendment No. 2 ("Amendment No. 2") amends the Schedule 13D first filed with the Securities and Exchange Commission on August 21, 2024 (the "Original Statement"), as amended and restated by Amendment No. 1 dated October 9, 2025, Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule 13D.

**Item 4. Purpose of Transaction**

TCNT sold the shares of the issuer's common stock for general operating purposes.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Items 5 of the Statement are hereby amended and restated as follows:

(a) - (b) The information requested by these paragraphs are incorporated herein by reference to the cover pages to this Amendment No. 1.

**(b)**
—

**(c)**
Since the most recent filing of Schedule 13D on October 9, 2025, the following transactions have occurred:

On January 28, 2026, TCNT sold 46,000 shares of Common Stock.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

TCNT directly holds 989,925 shares of Common Stock.

On January 1, 2026, Ainos KY and TCNT entered into a voting agreement (the "Voting Agreement") with respect to the voting stock of the Issuer held by TCNT. Pursuant to the Voting Agreement, TCNT has agreed to vote all of the voting stock of the Company that is current owns or will acquire in the future in the manner determined by Ainos KY in its sole discretion. The Voting Agreement will continue in effect until the first anniversary and shall automatically be extended for additional one (1) year periods unless the otherwise terminated. The Voting Agreement will cease to apply to a particular stockholder when the stockholder holds no shares in the Issuer.

Except as set forth herein, the reporting person has no other contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Taiwan Carbon Nano Technology Corporation

**Signature:** /s/ Chun-Hsien Tsai

**Name/Title:** Chairman, Chief Executive Officer

**Date:** 01/30/2026